#HaDEA #CancerMission
x.com/i/status/199...
#HaDEA #CancerMission
x.com/i/status/199...
If you weren’t able to attend but want to learn more, please feel free to contact the Communication and Dissemination Manager, Ben Moore, at bmoore@carrcommunications.ie
#HaDEA #CancerMission
✍️Sign up here: lnkd.in/dTfRAinJ
#HaDEA #CancerMission
If you weren’t able to attend but want to learn more, please feel free to contact the Communication and Dissemination Manager, Ben Moore, at bmoore@carrcommunications.ie
#HaDEA #CancerMission
A big thank you to them for helping spread word of our project that aims to advance early detection & risk assessment for ovarian cancer 💙
#HaDEA #CancerMission
cancerletter.com/clinical-rou...
A big thank you to them for helping spread word of our project that aims to advance early detection & risk assessment for ovarian cancer 💙
#HaDEA #CancerMission
cancerletter.com/clinical-rou...
✍️Sign up here: lnkd.in/dTfRAinJ
#HaDEA #CancerMission
✍️Sign up here: lnkd.in/dTfRAinJ
#HaDEA #CancerMission
#HaDEA #CancerMission
ecancer.org/en/news/2717...
#HaDEA #CancerMission
ecancer.org/en/news/2717...
Watch the full piece here 👇
www.rtp.pt/noticias/pai...
Watch the full piece here 👇
www.rtp.pt/noticias/pai...
The DISARM project has been featured by the Greek outlet Dnews, highlighting the importance of early detection, risk assessment, and smart digital tools for tacking ovarian cancer 💙
www.dnews.gr/eidhseis/sci...
The DISARM project has been featured by the Greek outlet Dnews, highlighting the importance of early detection, risk assessment, and smart digital tools for tacking ovarian cancer 💙
www.dnews.gr/eidhseis/sci...
See the collaboration, energy, and shared commitment driving our mission to transform ovarian cancer risk assessment and early detection 💙
www.youtube.com/watch?v=xvrm...
See the collaboration, energy, and shared commitment driving our mission to transform ovarian cancer risk assessment and early detection 💙
www.youtube.com/watch?v=xvrm...
2 days of collaboration, keynotes & big ideas:
🏛️ Ovarian cancer socioececonomic burden & the CanRisk tool
🔬 Liquid biopsy & clinical studies
🧬 PRS adaptation
👥 Citizen awareness & Platforms
An Exciting journey ahead , thank you to all partners! 💙
2 days of collaboration, keynotes & big ideas:
🏛️ Ovarian cancer socioececonomic burden & the CanRisk tool
🔬 Liquid biopsy & clinical studies
🧬 PRS adaptation
👥 Citizen awareness & Platforms
An Exciting journey ahead , thank you to all partners! 💙
We open with a keynote from Prof. Antonis Antoniou (University of Cambridge) on the CanRisk tool.
Today’s agenda: risk assessment in clinical studies, citizen awareness, strategies for adapting PRS to national populations and more!
We open with a keynote from Prof. Antonis Antoniou (University of Cambridge) on the CanRisk tool.
Today’s agenda: risk assessment in clinical studies, citizen awareness, strategies for adapting PRS to national populations and more!
This afternoon, partners aligned on clinical protocols and explored opportunities for policy development.
More updates coming tomorrow, stay tuned!
This afternoon, partners aligned on clinical protocols and explored opportunities for policy development.
More updates coming tomorrow, stay tuned!
This was followed by a fruitful discussion on liquid biopsy detection from our partners UNRF 👨🏫
Stay tuned for more updates throughout the day!
This was followed by a fruitful discussion on liquid biopsy detection from our partners UNRF 👨🏫
Stay tuned for more updates throughout the day!
This morning our Project Partners have gathered in Greece for the Disarm kick off meeting.
This morning's highlight is a keynote presentation from the World Ovarian Cancer Coalition on ‘The Socioeconomic Burden of Ovarian Cancer’. ⚕️
➡️ Follow for more updates!
This morning our Project Partners have gathered in Greece for the Disarm kick off meeting.
This morning's highlight is a keynote presentation from the World Ovarian Cancer Coalition on ‘The Socioeconomic Burden of Ovarian Cancer’. ⚕️
➡️ Follow for more updates!
We’re bringing partners together from across Europe to set the stage for advancing ovarian cancer risk assessment & early detection 🧬
Stay tuned for updates from Athens!
We’re bringing partners together from across Europe to set the stage for advancing ovarian cancer risk assessment & early detection 🧬
Stay tuned for updates from Athens!
@imperialcollegeldn.bsky.social's Imperial News, showcasing our mission to tackle ovarian cancer through better risk assessment and early detection 📰
🔗 Read the full feature here:
www.imperial.ac.uk/news/268373/...
@imperialcollegeldn.bsky.social's Imperial News, showcasing our mission to tackle ovarian cancer through better risk assessment and early detection 📰
🔗 Read the full feature here:
www.imperial.ac.uk/news/268373/...
It was wonderful to be featured alongside so many amazing projects under the EU's Cancer Mission 💙
ec.europa.eu/newsroom/rtd...
It was wonderful to be featured alongside so many amazing projects under the EU's Cancer Mission 💙
ec.europa.eu/newsroom/rtd...
On Monday, the DISARM consortium held a pre–kick-off online meeting to align on admin, financial & work package details, setting a strong base before our in-person kick-off in Athens next month. 🇬🇷
Stay tuned for more from our kick-off!
#HorizonEurope #OvarianCancer
On Monday, the DISARM consortium held a pre–kick-off online meeting to align on admin, financial & work package details, setting a strong base before our in-person kick-off in Athens next month. 🇬🇷
Stay tuned for more from our kick-off!
#HorizonEurope #OvarianCancer
@lifesciencenet.bsky.social
for featuring our press release on their website! 💻
If you haven't already, check out DISARM's first press release by clicking on the link below 🔗
www.lifescience.net/news/6551/ne...
@lifesciencenet.bsky.social
for featuring our press release on their website! 💻
If you haven't already, check out DISARM's first press release by clicking on the link below 🔗
www.lifescience.net/news/6551/ne...
Ovarian cancer is the deadliest gynaecological disease & 8th most common cancer for women globally.
We are changing how risk is assessed, bringing proven tech to routine care while validating new approaches💙
Ovarian cancer is the deadliest gynaecological disease & 8th most common cancer for women globally.
We are changing how risk is assessed, bringing proven tech to routine care while validating new approaches💙
DISARM, aims to advance risk assessment and early detection of ovarian cancer, aiming to make these life-saving approaches part of routine healthcare 🩺
Check it out below!
www.linkedin.com/pulse/press-...
DISARM, aims to advance risk assessment and early detection of ovarian cancer, aiming to make these life-saving approaches part of routine healthcare 🩺
Check it out below!
www.linkedin.com/pulse/press-...
With proven solutions & testing new innovations, DISARM aims to transform screening and give patients the best chance at survival 💙
With proven solutions & testing new innovations, DISARM aims to transform screening and give patients the best chance at survival 💙